- $1.84bn
- $1.82bn
- $105.97m
Brief: Zymeworks Says Authorizes $125 Million Share Repurchase Plan
Jazz Pharma jumps after cancer drug meets main goal in late-stage study
Brief: Zymeworks Announces Positive Herizon-GEA-01 Phase 3 Results Supporting Ziihera as Her2-Targeted Agent-Of-Choice And New Standard Of Care In First-Line Her2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma
U.S. STOCKS ON THE MOVE-Cytokinetics, Air Lease Corp, Lyft Inc
U.S. STOCKS ON THE MOVE-United Therapeutics, Signet Jewelers, Arrowhead
U.S. STOCKS ON THE MOVE-PepsiCo, Ionis Pharma, United Therapeutics
Zymeworks falls after halting cancer drug development
Brief: Zymeworks Announces Decision To Discontinue Clinical Development Of Zw171, A Mesothelin-Directed T Cell Engager
Zymeworks halts development of cancer drug after trial setback (updated)
Zymeworks halts development of cancer drug after trial setback
Zymeworks Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Zymeworks Q2 Operating Expenses USD 49.4 Million
Zymeworks Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Zymeworks Gets FDA OK for IND on ZW251, a Novel GPC3-Targeted Topoisomerase 1 ADC
Brief: Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer
Zymeworks Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Zymeworks Q1 Operating Expenses USD 52.723 Million
Zymeworks Inc expected to post a loss of 41 cents a share - Earnings Preview
Zymeworks Inc reports results for the quarter ended December 31 - Earnings Summary